Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBIT (2022 - 2025)

Historic EBIT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' EBIT fell 14458.34% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 5004.46%. This contributed to the annual value of -$3.1 million for FY2024, which is 9543.39% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' EBIT is -$53.2 million, which was down 14458.34% from -$47.6 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' EBIT peaked at $47.2 million during Q4 2024, and registered a low of -$53.2 million during Q3 2025.
  • For the 4-year period, ARS Pharmaceuticals' EBIT averaged around -$16.3 million, with its median value being -$15.4 million (2022).
  • Per our database at Business Quant, ARS Pharmaceuticals' EBIT tumbled by 22476.36% in 2023 and then skyrocketed by 56153.92% in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' EBIT stood at -$15.4 million in 2022, then skyrocketed by 33.78% to -$10.2 million in 2023, then soared by 561.54% to $47.2 million in 2024, then tumbled by 212.7% to -$53.2 million in 2025.
  • Its last three reported values are -$53.2 million in Q3 2025, -$47.6 million for Q2 2025, and -$37.2 million during Q1 2025.